Stock Research for ARFXF

ARFXF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARFXF Stock Chart & Research Data

The ARFXF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARFXF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARFXF Due diligence Resources & Stock Charts

The ARFXF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARFXF Detailed Price Forecast - CNN Money CNN View ARFXF Detailed Summary - Google Finance
Yahoo View ARFXF Detailed Summary - Yahoo! Finance Zacks View ARFXF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ARFXF Trends & Analysis - Trade-Ideas Barrons View ARFXF Major Holders - Barrons
NASDAQ View ARFXF Call Transcripts - NASDAQ Seeking View ARFXF Breaking News & Analysis - Seeking Alpha
Spotlight View ARFXF Annual Report - CompanySpotlight.com OTC Report View ARFXF OTC Short Report - OTCShortReport.com
TradeKing View ARFXF Fundamentals - TradeKing Charts View ARFXF SEC Filings - Bar Chart
WSJ View Historical Prices for ARFXF - The WSJ Morningstar View Performance/Total Return for ARFXF - Morningstar
MarketWatch View the Analyst Estimates for ARFXF - MarketWatch CNBC View the Earnings History for ARFXF - CNBC
StockMarketWatch View the ARFXF Earnings - StockMarketWatch MacroAxis View ARFXF Buy or Sell Recommendations - MacroAxis
Bullish View the ARFXF Bullish Patterns - American Bulls Short Pains View ARFXF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ARFXF Stock Mentions - StockTwits PennyStocks View ARFXF Stock Mentions - PennyStockTweets
Twitter View ARFXF Stock Mentions - Twitter Invest Hub View ARFXF Investment Forum News - Investor Hub
Yahoo View ARFXF Stock Mentions - Yahoo! Message Board Seeking Alpha View ARFXF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ARFXF - SECform4.com Insider Cow View Insider Transactions for ARFXF - Insider Cow
CNBC View ARFXF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARFXF - OTC Markets
Yahoo View Insider Transactions for ARFXF - Yahoo! Finance NASDAQ View Institutional Holdings for ARFXF - NASDAQ


Stock Charts

FinViz View ARFXF Stock Insight & Charts - FinViz.com StockCharts View ARFXF Investment Charts - StockCharts.com
BarChart View ARFXF Stock Overview & Charts - BarChart Trading View View ARFXF User Generated Charts - Trading View




Latest Financial News for ARFXF


ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
Posted on Thursday January 17, 2019

ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that it will participate in the NobleCon15 and the CanTech Investment Conferences. Members of ProMIS’ senior management will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis), and participate on discussion panels.


PMN.TO: How Can ProMIS Contribute to the AD Treatment Setting?
Posted on Thursday January 03, 2019

The prevailing consensus on the cause of Alzheimer’s Disease (AD) has evolved over the last decades. In the 1980s, amyloid plaques or tau tangles were broadly but exclusively identified as the cause of the disease and the research community embarked on a search for a therapy that addressed one of these etiologies. In 1991 the amyloid hypothesis was proposed, further focusing development efforts.


ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
Posted on Tuesday December 18, 2018

TORONTO and CAMBRIDGE, MA, Dec. 18, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will participate in several of the biotechnology industry's most well-attended annual conferences. At these events, company leadership will provide current and potential investors with an updated overview of its drug discovery and development programs for Alzheimer's, Parkinson's and ALS (amyotrophic lateral sclerosis).


ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
Posted on Monday December 17, 2018

Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.